clinical trial

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

[Nature Medicine] Investigators administered a recombinant bicistronic adeno-associated virus (AAV8) vector coding for both the light and heavy chains of the potent broadly neutralizing HIV-1 antibody VRC07 to eight adults living with HIV.

[Nature Communications] The authors showed that broadening the number of neoantigen-reactive CD8+ T cell populations between pre-treatment to three weeks post-treatment distinguished patients with controlled disease compared to patients with progressive disease in metastatic urothelial carcinoma treated with PD-L1-blockade.

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

[MediciNova, Inc.] MediciNova, Inc. announced that the FDA has completed its review of a Phase II clinical trial protocol to evaluate MN-001 (tipelukast) for the treatment of patients with non-alcoholic fatty liver disease, type 2 diabetes mellitus, and hypertriglyceridemia.

[VYNE Therapeutics Inc.] VYNE Therapeutics Inc. announced positive efficacy results from the Phase Ib segment of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis.